Form 4 filings across 2 companies. Net figures count open-market buys and sales only. EDGAR profile ↗
Lifetime net: +$117.1K
Reported holding is the most recent post-transaction share count on a Table I row.
How quickly this filer reports. Section 16 allows two business days from the transaction.
All 7 filings we hold were filed within the two-business-day deadline.
Counted in business days from the transaction date, or the deemed execution date where the filing reports one, excluding weekends and federal holidays. How this is measured · All late filings
The 10 most recent Form 4 transactions.
| Nov 18, 2025 | CRVO | CervoMed Inc. | PBUY | 1,500 | $7.95 | $11.9K | +11.1% | Open the original filing on SEC.gov |
| Nov 17, 2025 | CRVO | CervoMed Inc. | PBUY | 3,500 | $8.43 | $29.5K | +35.0% | Open the original filing on SEC.gov |
| Nov 14, 2025 | CRVO | CervoMed Inc. | PBUY | 10,000 | $7.57 | $75.7K | — | Open the original filing on SEC.gov |
| Oct 6, 2025 | CRVO | CervoMed Inc. | AGRANT◆ | 75,000 | — | — | — | Open the original filing on SEC.gov |
| Jul 1, 2025 | INZY | Inozyme Pharma, Inc. | DTOISS◆ | 145,000 | — | — | — | Open the original filing on SEC.gov |
| Jul 1, 2025 | INZY | Inozyme Pharma, Inc. | DTOISS◆ | 41,500 | — | — | — | Open the original filing on SEC.gov |
| Jul 1, 2025 | INZY | Inozyme Pharma, Inc. | UTENDR | 21,743 | $4.00 | $87K | -100.0% | Open the original filing on SEC.gov |
| Jun 25, 2025 | INZY | Inozyme Pharma, Inc. | AGRANT | 14,355 | $0.74 | $10.6K | +194.3% | Open the original filing on SEC.gov |